Synapse - Rachel Hamelers

Rachel Hamelers

Research Focus

Former Employee. Medicine; Research Stdy Asst II

Recent additions – View all

A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save
The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Co-authors at MSK

2

Hamlin
2

Horwitz
2

Moskowitz
2

Neylon
2

Noy
2

O'connor
2

Portlock
2

Straus
1

Dumitrescu
1

Gerecitano
1

Macgreg...
1

Palomba
1

Pappani...
1

Sarasohn
1

Zelenetz

Types of Work

Publications

Blood (1)
Molecular Cancer Therapeutics (1)